Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
Zentalis announced the first overall survival data for azenosertib from DENALI Part 1b, published ahead of a rapid oral presentation at ESMO Congress 2026 on October 23. In Cyclin E1-positive platinum-resistant ovarian cancer patients (n=48), median OS was 15.8 months versus 7.5 months in the Cyclin E1-negative subgroup, with no new safety signals as of the September 2, 2025 data cutoff.
Key figures
- Drug Name
- azenosertib
- Phase Of Trial
- Phase 2 (DENALI Part 1b); Phase 3 confirmatory ASPENOVA ongoing
- Part 1b enrolled
- 102
- Cyclin e1 negative n
- 46
- Cyclin e1 positive n
- 48
- Aspenova expected enrollment
- 420
- Median os cyclin e1 negative months
- 7.5
- Median os cyclin e1 positive months
- 15.8
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.